**WHAT IS CLAIMED IS**

1. A immunoassay method for a sample comprising the steps of:

a. contacting the sample with a specific binding ~~entity~~ reactive to human iNOS; ~~and~~

b. ~~revealing~~ the presences of human iNOS protein in said sample, said specific binding entity recognizing ~~a region of~~ human iNOS protein.

2. The method of claim 1 in which said specific binding entity is selected from the group consisting of: monoclonal antibodies, oligonucleotides, polymers as artificial antibodies, and phage display binding sites.

3. The method of claim 1 in which said region of human iNOS protein is selected from the group consisting of the loci: A-3, A-4, A3 & A4, F6, G11, and H1.

4. The method of claim 1 in which said immunoassay is selected from the group ~~comprising~~: direct, indirect, capture, competitive binding, and displacement.

5. The method of claim 1 in which said immunoassay is a clinical diagnostic assay.

6. The method of claim 1 in which said step of ~~revealing~~ detecting the presence of human iNOS protein ~~is~~ comprises a qualitative analysis.

7. The method of claim 1 in which said step of ~~revealing~~ detecting the presence of human iNOS ~~is~~ comprises a quantitative analysis.

8. An immunoassay method for a sample comprising the steps of:

a. contacting the sample with a ~~specific binding entity~~ monoclonal antibody reactive to mimics of human iNOS protein;

b. ~~revealing~~ detecting the presence of human iNOS protein in said sample, said specific binding entity being reactive to mimics of ~~a region of~~ human iNOS protein.

9. The method of claim 8 in which said ~~specific binding entity~~ monoclonal antibody is selected from the group consisting essentially of: peptides, recombinant peptides, fusion proteins, fusion peptides, phage displayed proteins, phage displayed peptides, peptide libraries, and peptide analogue libraries.

10. The method of claim 8 in which said region of human iNOS protein is selected from the group consisting of the loci: A-3, A-4, A3 & A4, F6, G11, and H1.

11. The method of claim 8 in which said immunoassay is selected from the group ~~comprising~~ consisting essentially of: direct, indirect, capture,

competitive binding, and displacement.

12. The method of claim 8 in which said immunoassay is a clinical diagnostic assay.

13. The method of claim 8 in which said step of detecting ~~revealing~~ the presence of human iNOS protein comprises ~~is~~ a qualitative analysis.

14. The method of claim 8 in which said step of detecting ~~revealing~~ the presence of human iNOS comprises ~~is~~ a quantitative analysis.

15. The method of claim 8 in which said specific binding entity is any one of the peptide analogues of Table VII.

16. The method of claim 8 in which said specific binding entity is any one of the peptide analogues of Table IX.

17. The assay of claim 8 which is of the type selected from the group consisting essentially of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture, and RIA.

18. The assay of claim 1 which is of the type selected from the group consisting of: IFA, linear or radial flow, Western Blot, ELISA, dip stick, fluorescent polarization, enzyme capture,

and RIA.

19. The method of claim 15 in which said specific binding entity is a peptide analogue having the sequence: VTQDDLQ.

20. The method of claim 16 in which said specific binding entity is a peptide analogue having the sequence: VQGILERV.

21. A immunoassay for a sample comprising;

a. a ~~specific binding entity~~ monoclonal antibody reactive to human iNOS; and

b. a ~~vehicle~~ medium for ~~revealing~~ detecting the presence of human iNOS according to said specific binding entity recognizing a region of human iNOS protein.